The Company has a platform of gene delivery on advanced on advanced viral systems and is underpinned by over 80 patent families one of the broadest one of the broadest patent assets in the field. The Company also has the collaboration with Sigma-Aldrich, and MOLMED Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer delivery and use .
The technology of Nobel laureate scientists Andrew Z. And Craig C. And her colleagues invented. The pioneering patent claims this technology for the first time for the first time in the United States by the United States Patent and Trademark Office 2003. Other patents issued in Australia and other U.S. And foreign applications are pending.
The TAXUS OLYMPIA registry deals one another the registration process and consists multiple and high-risk patient group, which real world usage pattern found in in clinical routine. One-year data been collected for a total of 22,345 patients in 57 countries today. Buenos Aires per cent 4.3 %age 4.3 %age per cent 3.8 %age 3.8 %age patients . All of these factors are difficult and impossible to predict accurately and many of which are outside our control. For a further list and description of this and other important risks and see Part I, our future operations, see Part I, forward looking statements risk factor in the our most recent annual report on Form 10 – K during Securities and Exchange Commission , which we to in Section II Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We oppose any intent or obligation to publicly update or revise any forward-looking statements reflecting any change in our expectations or in events, Service or circumstances on which any may based these expectations, and that affect the probability that actual results to differ from those prevailing in forward-looking statements is contain. This warning label applies to all forward-looking statements in this document is provided.